Limits...
Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.

Park HK, Kim H, Kim HG, Cho YM, Jung WY, Han HS, Hwang TS, Kwon GY, Lim SD - J. Korean Med. Sci. (2015)

Bottom Line: Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects.Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-γ.Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic implication in prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT
Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-activated transcription factor has been investigated as the target for cancer treatment as well as metabolic disorders. Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects. The aim of this study was to validate PPAR-γ expression in malignant and benign prostate tissues by immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). A total of 730 prostatic adenocarcinomas (PCAs) including 63 whole sections from radical prostatectomy specimens and tissue microarrays containing 667 PCAs were subject to immunostaining for two PPAR-γ antibodies. Twenty-five benign prostate tissues and PCAs were selected for investigating mRNA expression by quantitative real-time PCR. 10.7% of PCAs (78/730) showed cytoplasmic immunoreactivity of PPAR-γ and no nuclear immunoreactivity was noted in PCAs. Most benign prostatic glands showed negative immunoreactivity of PPAR-γ except for variable weak cytoplasmic staining in some glands. Nuclear immunoreactivity of PPAR-γ was noted some central zone and verumontanum mucosal epithelium. The constitutive PPAR-γ mRNA showed significantly lower level in PCAs compared to that in the benign tissues. There was no difference of PPAR-γ mRNA expression between low (≤7) and high (>7) Gleason score groups. There was no association of PPAR-γ mRNA level or cytoplasmic immunostaining with Gleason grade or pathologic stage. Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-γ. Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic implication in prostate cancer.

No MeSH data available.


Related in: MedlinePlus

PPAR-γ protein expression in positive control tissues by immunohistochemistry. Nuclear immunoreactivity in thyroid follicular carcinoma (A), urothelial carcinoma (B), and adipocytes in periprostatic tissue (C) (Original magnification: (A, C) ×400; (B) ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4414635&req=5

Figure 4: PPAR-γ protein expression in positive control tissues by immunohistochemistry. Nuclear immunoreactivity in thyroid follicular carcinoma (A), urothelial carcinoma (B), and adipocytes in periprostatic tissue (C) (Original magnification: (A, C) ×400; (B) ×200).

Mentions: Positive controls revealed nuclear immunoreactivity of PPAR-γ in thyroid follicular carcinoma, urothelial carcinoma of bladder and periprostatic adipocytes (Fig. 4A-C). No association between PPAR-γ cytoplasmic expression and clinicopathologic parameters including age, Gleason score and pathologic stage was noted (Table 2).


Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.

Park HK, Kim H, Kim HG, Cho YM, Jung WY, Han HS, Hwang TS, Kwon GY, Lim SD - J. Korean Med. Sci. (2015)

PPAR-γ protein expression in positive control tissues by immunohistochemistry. Nuclear immunoreactivity in thyroid follicular carcinoma (A), urothelial carcinoma (B), and adipocytes in periprostatic tissue (C) (Original magnification: (A, C) ×400; (B) ×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4414635&req=5

Figure 4: PPAR-γ protein expression in positive control tissues by immunohistochemistry. Nuclear immunoreactivity in thyroid follicular carcinoma (A), urothelial carcinoma (B), and adipocytes in periprostatic tissue (C) (Original magnification: (A, C) ×400; (B) ×200).
Mentions: Positive controls revealed nuclear immunoreactivity of PPAR-γ in thyroid follicular carcinoma, urothelial carcinoma of bladder and periprostatic adipocytes (Fig. 4A-C). No association between PPAR-γ cytoplasmic expression and clinicopathologic parameters including age, Gleason score and pathologic stage was noted (Table 2).

Bottom Line: Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects.Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-γ.Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic implication in prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

ABSTRACT
Peroxisome proliferator-activated receptor gamma (PPAR-γ), a ligand-activated transcription factor has been investigated as the target for cancer treatment as well as metabolic disorders. Recent studies have demonstrated that PPAR-γ ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects. The aim of this study was to validate PPAR-γ expression in malignant and benign prostate tissues by immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). A total of 730 prostatic adenocarcinomas (PCAs) including 63 whole sections from radical prostatectomy specimens and tissue microarrays containing 667 PCAs were subject to immunostaining for two PPAR-γ antibodies. Twenty-five benign prostate tissues and PCAs were selected for investigating mRNA expression by quantitative real-time PCR. 10.7% of PCAs (78/730) showed cytoplasmic immunoreactivity of PPAR-γ and no nuclear immunoreactivity was noted in PCAs. Most benign prostatic glands showed negative immunoreactivity of PPAR-γ except for variable weak cytoplasmic staining in some glands. Nuclear immunoreactivity of PPAR-γ was noted some central zone and verumontanum mucosal epithelium. The constitutive PPAR-γ mRNA showed significantly lower level in PCAs compared to that in the benign tissues. There was no difference of PPAR-γ mRNA expression between low (≤7) and high (>7) Gleason score groups. There was no association of PPAR-γ mRNA level or cytoplasmic immunostaining with Gleason grade or pathologic stage. Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-γ. Further studies are needed to assess the functional role of PPAR-γ and to validate its therapeutic implication in prostate cancer.

No MeSH data available.


Related in: MedlinePlus